Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation

Completed

Conditions studied: Chronic Liver Disease

In brief

The objectives of this study are: * To evaluate the ability of the Methacetin Breath Test (MBT) to detect hepatic decompensation events * To evaluate the relationship between liver Biopsy and clinical outcome and show that the MBT has a better predictive ability of clinical outcome than liver biopsy. * To evaluate the ability of the MBT to predict each of the individual liver related complications.

Key facts

Study ID

NCT02084160

Run by

Meridian Bioscience, Inc.

People needed

579

Starts

2014-03-01

Expected to finish

2018-11-01

Last updated by the study team

2022-12-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All subjects that aere enrolled in the previous Exalenz trial HIS-EX-408 or PLT-BID-1108

You may not qualify if…

• None

Where it is running

• Henry Ford Health System — Detroit, Michigan, United States
• Medical University of South Carolina — Charleston, South Carolina, United States
• Virginia Commonwealth University — Richmond, Virginia, United States
• Hadassah Medical Origanzation — Jerusalem, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.